Lyra Therapeutics Files 8-K Amendment on Disposal Costs
Ticker: LYRA · Form: 8-K/A · Filed: Jun 7, 2024 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K/A |
| Filed Date | Jun 7, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $3.9, $4.1 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, restructuring, disposal-costs
TL;DR
Lyra Therapeutics filed an 8-K/A amendment regarding exit/disposal costs. Details TBD.
AI Summary
Lyra Therapeutics, Inc. filed an amendment (8-K/A) on June 7, 2024, to its Form 8-K dated May 16, 2024. This amendment pertains to costs associated with exit or disposal activities. The filing does not disclose specific dollar amounts or detailed reasons for these costs.
Why It Matters
This filing indicates Lyra Therapeutics is undergoing restructuring or divesting certain assets, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings, especially concerning disposal costs, can signal significant operational changes or financial distress, warranting closer investor scrutiny.
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- 0001193125-24-157373 (accession_number) — Filing Accession Number
- 20240607 (date) — Filing Date
- May 16, 2024 (date) — Earliest Event Reported Date
- 480 Arsenal Way (address) — Principal Executive Offices
- Watertown, Massachusetts (location) — Principal Executive Offices Location
- 02472 (zip_code) — Principal Executive Offices Zip Code
FAQ
What specific exit or disposal activities are being reported by Lyra Therapeutics?
The filing does not specify the exact nature of the exit or disposal activities, only that it pertains to 'Cost Associated with Exit or Disposal Activities'.
When was the original Form 8-K filed that this is amending?
The original Form 8-K was dated May 16, 2024.
What is the accession number for this 8-K/A filing?
The accession number is 0001193125-24-157373.
What is the principal executive office address for Lyra Therapeutics?
The principal executive office is located at 480 Arsenal Way, Watertown, Massachusetts, 02472.
What is the SIC code for Lyra Therapeutics?
The Standard Industrial Classification (SIC) code is 3841, for Surgical & Medical Instruments & Apparatus.
Filing Stats: 881 words · 4 min read · ~3 pages · Grade level 14.2 · Accepted 2024-06-07 16:15:54
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share LYRA The Nasdaq
- $3.9 — it will incur charges of approximately $3.9 to $4.1 million in connection with the
- $4.1 million — incur charges of approximately $3.9 to $4.1 million in connection with the Workforce Reduct
Filing Documents
- d837500d8ka.htm (8-K/A) — 25KB
- 0001193125-24-157373.txt ( ) — 150KB
- lyra-20240516.xsd (EX-101.SCH) — 3KB
- lyra-20240516_lab.xml (EX-101.LAB) — 18KB
- lyra-20240516_pre.xml (EX-101.PRE) — 11KB
- d837500d8ka_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company's estimated charges associated with and implementation of the Workforce Reduction. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the important factors discussed under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on April 30, 2024 and its other filings with the SEC. Readers are urged to consider these factors carefully and under the totality of the circumstances when evaluating the forward-looking statements made in this Current Report on Form 8-K, and not to place undue reliance on any of them. Any such forward-looking statements represent management's reasonable estimates and beliefs as of the date of this Current Report on Form 8-K. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, other than as may be required by law, even if subsequent events cause its views to change.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 7, 2024 Lyra Therapeutics, Inc. By: /s/ Jason Cavalier Jason Cavalier Chief Financial Officer